Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.